DTX3

Across TCGA pan-cancer cohorts, DTX3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated DTX3 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DTX3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DTX3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where DTX3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.451	0.992	<.001	42	view →
PDAC	DFS	Tertile	III,IV	0.998	0.430	.002	20	view →
LSCC	OS	Median	III,IV	0.673	1.000	<.001	18	view →
CCRCC	OS	Median	II,III,IV	0.454	1.000	.014	6	view →
HNSC	OS	Tertile	All	0.783	0.943	.018	5	view →
UCEC	OS	Quartile	II,III,IV	0.500	1.000	.035	4	view →
GBM	OS	Median	All	0.261	0.515	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DTX3–LUAD (DFS)

Open the LUAD breakdown →